Bicycle Therapeutics (BCYC)
(Delayed Data from NSDQ)
$22.66 USD
+0.45 (2.03%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $22.60 -0.06 (-0.26%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
BCYC 22.66 +0.45(2.03%)
Will BCYC be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BCYC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BCYC
Are Medical Stocks Lagging Bicycle Therapeutics (BCYC) This Year?
Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio
BCYC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Bicycle Therapeutics (BCYC) Stock Outpacing Its Medical Peers This Year?
Bicycle Therapeutics (BCYC) Up as PIPE Funding Set to Make $555M
Wall Street Analysts Think Bicycle Therapeutics (BCYC) Could Surge 85.52%: Read This Before Placing a Bet
Other News for BCYC
PepGen Appoints Afsaneh Mohebbi, Ph.D., as SVP, Portfolio and Program Management and Dave Borah, CFA, as SVP, Investor Relations and Corporate Communications
Omega Therapeutics Announces Election of Richard N. Kender to Board of Directors
Remix Therapeutics™ Appoints Maria Koehler, M.D., Ph.D., as an Independent Board Director
Tracking Baker Brothers Portfolio - Q1 2024 Update
Analysts Are Bullish on Top Healthcare Stocks: Bicycle Therapeutics (BCYC), Replimune Group (REPL)